|Chemical and physical data|
|Molar mass||145.39 kg/mol g·mol−1|
|(what is this?)|
Johnson & Johnson licensed the drug from Amgen in a deal valued at around US$425 million in 2008. In 2016 Johnson & Johnson discontinued all phase III trials of fulranumab and returned the rights to its originator. The company said the decision was based on "strategic portfolio prioritisation and was not based on any emerging safety concerns from the phase III clinical studies with fulranumab" in osteoarthritic pain.
- Monoclonal Antibodies Targeted Against Nerve Growth Factor For the Treatment of Chronic Pain, By Ken Verburg, PhD - Medicines Development Group, Pfizer Inc., Arthritis Advisory Committee Meeting, 12 March 2012
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab" (PDF). American Medical Association.
- J&J drops NGF blocker fulranumab, Article by Phil Taylor, 4th April 2016, PMLiVE
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|